Topical vitamin D analogs are not approved for use in pediatric patients.
The FDA has approved dupilumab, a targeted biologic, for use in children 6-11 years of age with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are inappropriate.
Crisaborole, a PDE-4 inhibitor, is approved by the FDA for use in infants and children 3 months or older.
Topical administration of the calcineurin inhibitor pimecrolimus is approved as a second-line therapy for the short-term treatment of atopic dermatitis in children 2 years and older who are not immunocompromised, whose disease is not adequately controlled with topical prescription therapies, or when those therapies are inappropriate.
Learn more about medication in atopic dermatitis.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: William D. James. Fast Five Quiz: Severe Pediatric Atopic Dermatitis - Medscape - Mar 15, 2021.